Drug Profile
Research programme: therapeutics for mood and brain disorders - Janssen/University of Toronto
Latest Information Update: 28 Oct 2018
Price :
$50
*
At a glance
- Originator Janssen Inc; University of Toronto
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Mood disorders
Most Recent Events
- 28 Oct 2018 No recent reports of development identified for research development in Alzheimer's-disease in Canada
- 28 Oct 2018 No recent reports of development identified for research development in Mood disorders in Canada
- 15 Sep 2014 Janssen and University of Toronto agree to co-develop therapeutics in Canada for Mood disorders and Alzheimer's disease